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Alessandra Agresti,3 Raffaele Coletti,1 Daniel J. Antoine,4 Ralf Heermann,5 Kirsten Jung,5 Sven Reese,6 Iina Laitinen,7
Markus Schwaiger,7 Axel Walch,8 Markus Sperandio,2,9 Peter P. Nawroth,10 Christoph Reinhardt,11,12 Sven Jäckel,11,12
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Deep venous thrombosis (DVT) is one of the most common cardiovascular diseases,
but its pathophysiology remains incompletely understood. Although sterile inflammation
has recently been shown to boost coagulation during DVT, the underlying molec-
ular mechanisms are not fully resolved, which could potentially identify new anti-
inflammatory approaches to prophylaxis and therapy of DVT. Using a mouse model of
venous thrombosis induced by flow reduction in the vena cava inferior, we identified
blood-derived high-mobility group box 1 protein (HMGB1), a prototypical mediator of
sterile inflammation, to be a master regulator of the prothrombotic cascade involving
platelets andmyeloid leukocytes fosteringocclusiveDVT formation. Transfer of platelets
into Hmgb12/2 chimeras showed that this cell type is the major source of HMGB1,
exposing reduced HMGB1 on their surface upon activation thereby enhancing the
recruitment of monocytes. Activated leukocytes in turn support oxidation of HMGB1
unleashing its prothrombotic activity and promoting platelet aggregation. This potenti-
ates the amount of HMGB1 and further nurtures the accumulation and activation of
monocytes through receptor for advanced glycation end products (RAGE) and Toll-like
receptor 2, leading to local delivery of monocyte-derived tissue factor and cytokines.
Moreover, disulfide HMGB1 facilitates formation of prothrombotic neutrophil extracellular traps (NETs)mediated byRAGE, exposing
additional HMGB1 on their extracellular DNA strands. Eventually, a vicious circle of coagulation and inflammation is set in motion
leading to obstructive DVT formation. Therefore, platelet-derived disulfide HMGB1 is a central mediator of the sterile inflammatory
process in venous thrombosis and could be an attractive target for an anti-inflammatory approach for DVT prophylaxis. (Blood. 2016;
128(20):2435-2449)
Introduction
Deep venous thrombosis (DVT) and its major complication, venous
thromboembolism, constitute major health care issues associated with
substantial morbidity and mortality. Despite the effort to identify risk
factors and to develop new preventive strategies, the incidence of DVT
is increasing.1 Prevention of DVT in hospitalized patients is usually
achieved by anticoagulation, for example, using heparins or more re-
cently by non-vitamin K oral anticoagulants. However, anticoagulants
carry along an increased risk of bleeding due to impaired hemostasis;
hence, prevention of DVT without compromising the hemostatic
system would be preferable. Recently, we and others have shown
that DVT has to be considered an aberrant sterile inflammatory
process, where innate immunity drives clot formation.2-7 In
particular, monocytes and neutrophils support coagulation during
DVT by delivering tissue factor (TF), the activator of the extrinsic
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coagulation pathway, and through the formation of neutrophil
extracellular traps (NETs), negatively charged DNA structures that
activate coagulation and platelets.2-7 However, how exactly the
sterile inflammatory process is initiated and maintained during DVT
remains incompletely understood.8
Sterile inflammation is characterized by an immune response in the
absence of pathogenic organismswhere cell death leads to the releaseof
danger-associated molecular patterns (DAMPs).9 Once in the extra-
cellular space, DAMPs elicit a strong immune response that serves
to remove dead cells, but may result in additional damage due to
inflammatory off-target effects.10 Not only can necrosis lead to the
release of DAMPs, but immune cells as well as platelets can also
actively release these mediators.11-13 High-mobility group box 1
(HMGB1), a nuclear protein attached to DNA which stabilizes
nucleosome formation and is involved in the regulation of gene
expression, is one of the prototypical DAMPs.14 Once released into
the extracellular space, HMGB1 elicits and fine-tunes leukocyte
recruitment and activation. HMGB1 functionality depends on the
redox state of the protein: whereas the reduced form primarily serves
as a chemoattractant, the oxidized intermediate induces leukocyte
activation and release of proinflammatory cytokines; these effects are
lost in the terminally oxidized sulfonyl form.15,16 In addition,
HMGB1 has recently been reported to induce platelet aggregation in
vitro and in vivo in the setting of microvascular thrombosis.17,18
However, whether and how different HMGB1 redox forms
contribute to sterile inflammation and clot formation during macro-
vascular DVT remains elusive.
Here, we used a mouse model of flow reduction in the inferior vena
cava (IVC) to identify a novel function of HMGB1 in coordinating
macrovascular venous thrombosis.6,19 We show that blood cells,
particularly platelets, deposit reduced HMGB1 on the luminal aspect
of venous endothelial cells early in the process of DVT formation.
Pharmacological inhibition or loss of blood-derived HMGB1 prevents
DVT formation. Platelet-derived HMGB1 propagates DVT by
operating at least 3 different mechanisms: (1) by triggering monocyte
recruitment and supportingmonocyteTF production; (2) by facilitating
the formation of prothrombotic NETs providing additional HMGB1,
and (3) by increasing platelet accumulation and aggregation. These
effects of HMGB1 involve receptor for advanced glycation end
products (RAGE), Toll-like receptor 2/4 (TLR2/4), and depend on the
redox status of the protein. Hence, we identify HMGB1 as a promising
new target in the sterile inflammatory response, which eventually
activates the coagulation system and triggers DVT.
Methods
Animals
C57BL/6,Balb/c,Myd882/2, andTlr42/2micewere obtained fromThe Jackson
Laboratory or Janvier (Balb/c) and generated as described.20,21 Tlr22/2 mice
were generated asdescribed.22Rage2/2micewere providedbyP.P.N.23C57BL/
6micewere used as control forMyd882/2,Tlr22/2,Rage2/2, andTlr42/2mice,
which have been backcrossed to aC57Bl/6 background for at least 7 generations.
Hmgb12/2 chimeras were generated as described from heterozygous crossings,
and fetal liver cells of Hmgb12/2 and Hmgb11/1 siblings were injected into
Balb/c mice for generation of chimeras.24 Heterozygous LysMeGFP/1 and
CX3CR1GFP/1 knock-in mice were generated as described.25,26 All procedures
performed on mice were approved by the local legislation on protection of
animals (Regierung von Oberbayern, Munich, Germany). HMGB1-deficient
mice were maintained in Ospedale San Raffaele, under protocols reviewed and
approved by the Animal Care andUse Committee of Ospedale San Raffaele and
by the Ministry of Health of Italy.
Mouse model of flow restriction in the IVC
After a median laparotomy, the IVC was exposed and a space holder was
positioned followed by a narrowing ligature. Subsequently, the wire was
removed to avoid complete vessel occlusion. Side branches were not ligated
or manipulated. All groups were age, sex, and weight matched. Mice with
bleedings or any injury of the IVC during surgery were excluded from further
analysis. BoxA (500mg; HMGBiotech) was administered IV into the tail vein
of Balb/c mice before surgery; phosphate-buffered saline (PBS) was used as
control. Anakinra (1 mg/kg) was given subcutaneously (s.c.) 1 hour before
flow reduction and then every 24 hours into C57Bl/6 mice; NaCl was used as
control. 3S- and disulfideHMGB1were injected IV at 0.5mg/kg immediately
before the surgery and 24 hours afterward into Hmgb12/2 chimeras. For
nuclear staining, propidium iodide 10 mg/kg body weight was injected IV 30
minutes before the mice were sacrificed. For thrombus weight measurement
after 48 hours, the IVCwas excised just below the renal veins and proximal to
the confluence of the common iliac veins.
Intravital epifluorescence microscopy
Murine platelets were isolated from whole blood and labeled with Rhodamine
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Figure 1. Presence of HMGB1 in the developing
venous thrombus. (A) Immunofluorescence staining
of cross sections of the IVC for HMGB1 (green) and
DAPI (blue) 1, 6, 12, and 48 hours after flow reduction.
Arrowheads show HMGB1 deposition, dotted line
indicates endothelium; bar, 200 mm. (B) Left, Scanning
electron microscopy of the IVC 6 hours after flow
reduction, showing the intact endothelium covered by
cell aggregates and fibrin; bar, 5 mm. Right, Three-
dimensional reconstruction of images from intravital
2-photon microscopy showing the vessel wall (second
harmonic generation, red), with adherent platelets
(yellow) and neutrophils (green); bar, 50 mm. Box,
Platelet-myeloid leukocyte aggregates indicated by
arrowheads at higher magnification. (A-B) Images
representative of n 5 3 experiments.
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was injected IV or CX3CR1GFP/1mice were used. Imagingwas performedwith
an Olympus BX51WI microscope using a 203 (NA 0.95) water-immersion
objective and an ORCA-ER CCD camera (Hamamatsu).
Intravital 2-photon microscopy
A TrimScope (LaVision Biotech) connected to an upright Olympus microscope
was used, equipped with a MaiTai laser (Spectra-Physics) and a 203 water-
immersion objective (numerical aperture 0.95; Olympus). LysMeGFP/1mice and
platelets labeled with Cell Tracker violet (Invitrogen) were used.
Ultrasound
Ultrasound examinations were performed using the MyLab One VET system
(Esaote SpA) adapted to a SL 3116 linear probe of 15 to 22 MHz.
Computed tomography
Mice were imaged with the Inveon small animal positron emission tomography/
computed tomography (CT) scanner (Siemens). As contrast agent, 0.1 mL of
eXIA 160-XL (Binitio Biomedical Inc) was injected IV. CT projections were
acquired as described previously (exposure time of 400 ms, x-ray voltage
80 kVp, anode current 400 mA for a full 360° rotation).6
Generation of fetal liver cell chimeras
For generation of fetal liver chimeras, 63 106 fetal liver cells ofHmgb11/1 and
Hmgb12/2 animals were injected into the tail vein of irradiated (650 rad) Balb/c
mice. Six to eight weeks after transplantation, thrombus formation was induced.
Transfusion of platelets and neutrophils
Platelets were isolated from Balb/c mice or Hmgb12/2 chimeras and 150 000
were injected into the tail vein before the flow reduction of the IVC was
performed. Neutrophils were isolated from the bone marrow of Balb/c mice
by differential gradient centrifugation using an isotonic discontinuous Percoll
gradient (72%/64%/52%) at 4°C; Ly6G1 cells were .90% as determined by
fluorescence-activated cell sorting. Neutrophils (23 106) were injected into the
tail vein before surgery.
Immunofluorescence staining of frozen sections
The IVC was embedded in optimal cutting temperature compound, frozen at
280°C, and was cut with a cryotome (CryoStar NX70 Kryostat; ThermoFisher
Scientific) into 4-mmsections. Specimenswerefixedwith 4% formaldehyde and
blocked with the respective serum. The sections were incubated with primary
antibodies for CD41 (MWReg30, BDBiosciences; isotype: rat immunoglobulin
G1 [IgG1], Abcam), Ly6G (clone 1A8, BD Biosciences; isotype: rat IgG2a,
eBioscience), myeloperoxidase (MPO) (rabbit polyclonal, DAKO; isotype:
rabbit immunoglobulin fraction, DAKO), F4/80 (clone Cl:A3-1, AbD Serotec;
isotype: rat IgG2b, eBioscience), and HMGB1 (rabbit polyclonal, Abcam;
isotype: rabbit immunoglobulin fraction, DAKO). Next, Alexa-conjugated
secondary antibodies (Invitrogen) were used for detection. DNA was stained
with 49,6-diamidino-2-phenylindole (DAPI) (Invitrogen). Images were acquired
using a Zeiss Axio imager microscope with an AxioCam. For quantification of
NET formation 3 distinct parameters had to be met: (1) extracellular DNA
protrusions had to be present, (2) the protrusion had to originate from cells
staining positive for Ly6G, and (3) the structures had to be decorated withMPO.
Only if all of these criteria were fulfilled could a structure be defined as NET and
be included into the quantification.
Scanning electron microscopy
The IVC was perfused with PBS, followed by perfusion fixation with 1%
phosphate-buffered glutaraldehyde. The veins were mounted with carbon paint,
sputter-coated with platinum, and examined using a field emission scanning
electron microscope (JSM-6300F; Jeol Ltd).28
SPR spectroscopy and Interaction Map analysis
Surface plasmon resonance (SPR) assays were performed at 25°C in a Biacore
T200 using carboxymethyl dextran sensor chips (CM5 Sensor Chip Series S;
GE Healthcare) in HBS-EP1 buffer (GE Healthcare). First, the chips were
equilibrated with HBS-EP1 buffer until the dextran matrix had swollen. Then,
the chips were coated with anti-His antibodies (Biacore His-capture kit;
GE Healthcare), so that the chip surface allows for complete regeneration of His-
taggedmolecules froma sensor chip.Then, 2 of the 4flowcells oneach sensor chip
were activated by injecting a 1:1 mixture of N-ethyl-N-(3-dimethylaminopropyl)
carbodiimide hydrochloride andN-hydroxysuccinimide using the standard amine-
coupling protocol. Both flow cells were then loaded with a final concentration of
50 mg/mL anti-His antibody in 10 mM acetate (pH 4.5) using a contact time of
420 seconds so that the surfaces contained antibody densities equivalent to
;14 000 resonance units (RU). Free binding sites on the flow cells were saturated
by injection of 1 M ethanolamine/HCl (pH 8.0). Preparation of chip surfaces was
carried out at a flow rate of 10 mL per minute. Analyses of interaction between
RAGE-His and the 3 HMBG1 derivatives were performed in HBS-EP1 buffer.
First, 20 mg/mL mouse RAGE-His (Sino Biological Inc) was captured onto the
secondflowcell using a contact time of 60 seconds at a constantflow rate of 10mL
per minute, followed by a stabilization time of 10 seconds so that ;1000 RU
of RAGE-His were captured. Then, increasing concentrations (1, 10, 25, 50 nM,
23 100 nM, 250, 500, 1000, and 2000 nM) of nonoxidizable 3S-HMBG1,
disulfide HMBG1, and sulfonyl HMGB1 (HMGBiotech) were injected over both
flow cells using a contact time of 180 seconds each and a final dissociation step of
600 seconds at a flow rate of 30 mL per minute. After each cycle, the chip was
regenerated by injection of 10mMglycine (pH 1.5) for 60 seconds at aflow rate of
30 mL per minute over both flow cells, which completely removed RAGE-His
from the surface. Sensorgramswere recordedusingBiacoreT200Control software
2.0 and analyzed with Biacore T200 Evaluation software 2.0. The surface of flow
cell 1 was used to obtain blank sensorgrams for subtraction of the bulk refractive
index background. The referenced sensorgramswere then normalized to a baseline
of 0. Spikes in the sensorgrams at the start and the end of the injections emerged
from the run-time difference between the flow cells on each chip. InteractionMap
(IM)analysiswasperformed todifferentiate independent bindingevents in theSPR
data and calculations were performed on the Ridgeview diagnostic server
(RidgeviewDiagnostics).29 The resulting files were then evaluated for spots in the
TraceDrawer 1.5 software, and the IM spots were quantified.
Mass spectrometry
Platelet-rich plasma from healthy human donors was isolated as described and,
where indicated, platelets were activated group with thrombin (0.1 U/mL).30
Platelets and supernatant were separated by centrifugation and incubated
with 10 mM iodoacetamide, followed by 30 mM dithiothreitol and 90 mM
N-ethylmaleimide. Platelets were lysed (RIPA lysis buffer; ThermoFisher
Scientific) and stored at 280°C. Characterization of HMGB1 redox
modifications were determined as described previously by tandem mass
spectrometry.31,32
Reverse transcriptase polymerase chain reaction
Monocytes were isolated from healthy human donors (purity .90%) and
incubated with different redox forms of HMGB1 and lipopolysaccharide (LPS)
as positive control for 3 hours. RNA was isolated and template complementary
DNA was synthesized from 2 mg of total RNA using the High Capacity cDNA
Archive kit (Applied Biosystems) and applied in SybrGreen assays. Themurine
sequences of TF, interleukin-6 (IL-6), and IL-1b were detected by QuantiTect
primer assays (Qiagen).
Whole-blood aggregometry
Platelet aggregation was analyzed using whole blood by multiplate impedance
platelet aggregometry (Dynabyte) as described.30 Blood from healthy human
donors was anticoagulated with hirudin and stimulated with different redox
forms of HMGB1 as indicated compared with buffer. In 1 set of experiments,
anticoagulated whole blood was incubated with the different HMGB1 redox
forms for 30 minutes followed by stimulation with adenosine 59-diphosphate
(ADP) (2 mM).
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Figure 2. Blood-derived HMGB1 causes venous thrombosis. (A) Thrombus weight in Balb/c mice treated with PBS (n 5 8) compared with BoxA (n 5 6). (B) Left,
Immunofluorescence staining of cross-sections of the IVC for propidium iodide (PI) (red) and DAPI (blue) 6 hours after flow reduction. Dotted line indicates endothelium; bar,
200 mm. Right, Higher magnification of intraluminal propidium iodide–positive cells (arrowheads); bar, 70 mm. (C) Immunofluorescence staining of cross-sections of the IVC 1,
6, and 12 hours after flow reduction for CD41 (red) and HMGB1 (green). Nuclei are counterstained with DAPI (blue). Dotted line indicates endothelium; bar, 100 mm. Images
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NET formation
Blood from healthy human donors was collected in lithium-heparin tubes and
centrifugedwithFicoll PaquePlus.Erythrocyteswere lysed andneutrophilswere
plated on poly-L-lysine–coated coverslips and incubated for 1 hour with buffer,
disulfide, sulfonyl, or 3S- HMGB1 (1 mg/mL) in the presence of 20 mg/mL
aprotinin andfixedwith acetone. Sampleswere blockedwith 5%goat serum and
stained with a rabbit anti-human MPO antibody (polyclonal; DAKO) followed
by a secondary antibody (goat anti-rabbit AlexaFlour 594; Invitrogen). DNA of
cell nuclei was stained with Hoechst.
Thromboelastometry
Citrated whole blood from C57BL/6 mice which received 2 mg/kg 3S-,
disulfide, or sulfonyl HMGB1 was compared with buffer. For extem
measurements, blood was recalcified by adding startem reagent, whereas
the coagulation was initiated by extem reagent (Tem Innovations). In
Fibtem measurements, platelets were inactivated via cytochalasin D. For
analysis, a rotation thromboelastometry device was used (ROTEG 05;
Pentapharm).
Statistical analysis
All data are shownasmean6 standard error of themean (SEM), unless indicated
otherwise. Thrombus weight was tested for normal distribution using the
Kolmogorov-Smirnov test and the independent samples t test was performed to
comparegroups (SPSS).More than2groupswere comparedusing the analysisof
variance (ANOVA) followed by least significant difference (LSD)–post hoc test.






























































Figure 3. Redundant pattern recognition receptors
mediate the prothrombotic effects of HMGB1. (A)
Thrombus weight in C57Bl/6 mice (n 5 32) compared
with Tlr22/2 mice (n 5 12), Tlr42/2 mice (n 5 12),
Rage2/2 mice (n5 14),Myd882/2 mice (n5 12). Lines
indicate mean. One-way ANOVA followed by LSD–
post hoc test was used to compare results between
groups. (B) Thrombus weight in C57Bl/6 mice receiving
vehicle (n 5 13) compared with anakinra s.c. (n 5 8).
Lines indicate mean. The Student t test was used to
compare results between groups.
Figure 2 (continued) representative of n 5 3 experiments. (D) Immunofluorescence staining of cross-sections of the IVC 48 hours after flow reduction. Top, Presence of
HMGB1 on NETs (arrowheads) as shown by staining for HMGB1 (green), Ly6G (red), and DAPI (blue); bar, 20 mm. Bottom, HMGB1 (green) colocalizes with platelets (red).
Dotted line indicates endothelium; bar, 100 mm. Nuclei are counterstained with DAPI (blue). Images representative of n 5 3 experiments. (E) Thrombus weight in Hmgb11/1
fetal liver cell chimeras (n 5 7) compared with Hmgb12/2 chimeras (n 5 6). (F) Thrombus weight in Hmgb12/2 bone marrow chimeras (n 5 6) compared with Hmgb12/2
chimeras receiving wild-type platelets (n 5 10), Hmgb12/2 platelets (n 5 8), or wild-type neutrophils (n 5 9). (A,E,F) Line indicates mean. The Student t test was used to
compare results between 2 groups, 1-way ANOVA followed by LSD–post hoc test for 3 groups.
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Results
Progressive accumulation of HMGB1 in the developing
venous thrombus
Toexamine the importanceofHMGB1 for venous thrombosis,weused
a previously described mouse model of flow reduction in the IVC,6
which can be monitored noninvasively by Doppler ultrasound
(supplemental Figure 1A; supplemental Video 1-2, available on the
BloodWeb site). After 48 hours, a thrombus develops upstream of the
stenosis in the IVC as shown by CT in vivo (supplemental Figure 1B;
supplemental Video 3). To our surprise, we observed that HMGB1
progressively accumulates at the luminal aspect of the IVCendothelium
and can already be detected prior to thrombus formation. As early as
1 hour after induction of flow restriction, small amounts of HMGB1
are observed close to the endothelium (Figure 1A). At 6 hours, the
endothelium is decorated by large amounts ofHMGB1,whichfill the
entire IVC lumen at 12 hours. Local HMBG1 deposition is paralleled
by the gradual accumulation of leukocyte-platelet aggregates as
shown by electron and intravital 2-photon microscopy (Figure 1).
HMGB1 in DVT originates from platelets and neutrophils
Because HMGB1 progressively accumulates inside the IVC following
flow restriction, we next assessed whether this mediator of sterile
inflammation is of any biological relevance for the thrombotic
processes driving DVT formation. To test this, we determined the
effect of pharmacological inhibition ofHMGB1onDVTdevelopment.
Briefly, we treated Balb/c mice prior to flow restriction with the
HMGB1 inhibitor BoxA, which has been reported to attenuate sepsis
as well as hepatitis B virus–induced hepatitis.15,18,33 BoxA treatment
resulted in significantly decreased thrombus weight and also showed a
trend toward amoderately reduced incidence ofDVT (Figure 2A). This
suggests that HMGB1 propagates and accelerates thrombus formation.
But what is the source of luminal HMGB1 deposition during DVT
formation?HMGB1 can get access to the extracellular compartment by
release fromnecrotic cells. However, only very fewnecrotic cells could
beobservedwithin the lumenof the IVC in the initial stagesofDVTand
endothelial cell necrosis was virtually absent (Figure 2B). Besides its
passive leakage from dead cells, HMGB1 can also be actively released
by hematopoietic cells, including leukocytes and platelets.11-13 To
dissect the source ofHMGB1,we stained for thisDAMP indeveloping
venous thrombi. At early stages of DVT, most of HMGB1 was
associated with platelets (Figure 2C), which have been reported to
expose HMGB1 on their surfaces upon activation.11,12,34,35 At later
stages, we found colocalization of HMGB1 not only with platelets, but
also with NETs (Figure 2D).
To address the importance of blood cell-derived HMGB1 for
venous thrombogenesis, we next generated bone marrow chimeras
from fetal liver cells of Hmgb12/2 mice. Hmgb12/2 fetal liver cell
chimeras showed significantly reduced thrombus weight and also a
reduced incidence of DVT formation compared with Hmgb11/1
chimeras (Figure 2E). Next, we dissected the exact cellular source of
hematopoietic cell-derived HMGB1 that triggers thrombus formation.
To evaluate the importance of platelet- or neutrophil-derived HMGB1
on DVT, we infused wild-type platelets or wild-type neutrophils into
Hmgb12/2 bone marrow chimeras. Wild-type platelets fully restored
DVTformation comparedwithHmgb12/2platelets,whereaswild-type
neutrophils (P 5 .096) had no significant effect (Figure 2F).
Correspondingly, no HMGB1 could be detected within the vessel
lumen of Hmgb12/2 chimeras, but the amount of HMGB1 was
increased in chimeras supplementedwithwild-type platelets, and to a
lesser degree in chimeras supplemented with wild-type neutrophils
(supplemental Figure 1C).
Redundant pattern recognition receptors mediate the
prothrombotic effects of HMGB1
Having identified blood-borneHMGB1 as amajor propagator of DVT,
we next addressed the importance of distinct receptors in mediating
HMGB1’s prothrombotic effects (Figure 3A). First, we focused on
TLR2, which is expressed onmyeloid leukocytes as well as platelets.36
Genetic ablation of this receptor decreased the incidence of DVT,
but had no significant effect on thrombus weight. Another well-
characterized receptor for HMGB1 is TLR4, which is expressed on
myeloid leukocytes, platelets, and endothelial cells.37 Loss of TLR4
had no significant effect on DVT formation. The HMGB1-RAGE axis
has been shown to be important for mediating leukocyte accumulation
and subsequent tissue damage.11,38,39 Rage2/2 mice also showed no
significant reduction in DVT formation. Because none of these pattern
recognition receptors could significantly decrease thrombus formation,
we tested whether combined inhibition, through deficiency of the
adaptor molecule Myd88, which is involved in downstream signaling
of many TLRs including TLR2, TLR4, as well as RAGE, would
result in amore pronounced phenotype.14,40 Indeed,Myd882/2mice
had significantly reduced thrombus weight and a low incidence of
DVT (Figure 3A). BecauseMyd88 is also important for IL-1 receptor
signaling, we analyzed the contribution of this pathway to venous
thrombosis by using an IL-1 receptor antagonist inC57Bl/6mice, but
this treatment had no influence on DVT (Figure 3B).41 Taken
together, the above data show that TLR2, TLR4, and RAGE play
redundant functions during DVT and only combined deficiency in
converging signaling pathways of these receptors inhibits thrombus
formation.
HMGB1 influences neutrophil recruitment and NET formation
Because blood-derived HMGB1 facilitates and propagates venous
thrombosis, we next focused on the underlying cellular and molecular
mechanisms. Previously, we and others have shown that in venous
thrombosis, clot formation depends on leukocyte recruitment.6,42,43
Figure 4. HMGB1 induces NET formation trough RAGE in DVT. (A-I) Quantification of neutrophils and NETs. Results are mean 6 SEM. (A) BoxA (n 5 5) compared with
control (n 5 5). (B) Immunofluorescence staining for Ly6G (red) and MPO (green) from cross-sections of the IVC 48 hours after flow reduction of BoxA-treated (bottom) or
control mice (top). Nuclei are counterstained with DAPI (blue); bar, 200 mm. (C) Hmgb12/2 (n 5 3) fetal liver cell chimeras compared with Hmgb11/1 chimeras (n 5 5). (D)
Immunofluorescence staining for Ly6G (red) and MPO (green) from cross-sections of the IVC 48 hours after flow reduction of Hmgb11/1 (top) or Hmgb12/2 fetal liver cell
chimeras (bottom). Nuclei are counterstained with DAPI (blue); bar, 200 mm. (E) Quantification of NETs in Rage2/2 mice compared with control (n 5 5 each). (F)
Quantification of NETs in Tlr22/2 mice compared with control (n 5 3 each). (G) Quantification of NETs in Tlr42/2 mice compared with control (n 5 3 each). (H) Quantification
of NETs inMyd882/2 mice compared with control (n5 3 each). (I) Left, NET formation capacity shown as NETs/neutrophil (n5 5 each) in Hmgb12/2 chimeras compared with
Hmgb12/2 chimeras receiving wild-type platelets or wild-type neutrophils. Dotted line indicates mean in Hmgb11/1 bone marrow chimeras. Right, Immunofluorescence
staining for Ly6G (red) and MPO (green) from cross-sections of the IVC 48 hours after flow reduction in Hmgb12/2 chimeras compared with Hmgb12/2 chimeras receiving
wild-type platelets, Hmgb12/2 platelets or wild-type neutrophils. (n 5 3 each). Nuclei are counterstained with DAPI (blue); bar, 200 mm. The Student t test was used to
compare results between 2 groups, 1-way ANOVA followed by LSD–post hoc test for 3 groups.
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Figure 5. Platelet derived HMGB1 promotes monocyte recruitment. (A-G) Left, Quantification of monocytes. Results are mean 6 SEM. Right, Immunofluorescence
staining for F4/80 (red) from cross-sections of the IVC. Nuclei are counterstained with DAPI (blue); arrowheads indicate individual monocytes at higher magnification; bar,
200 mm. Images representative of n 5 3 experiments. (A) BoxA compared with control (n 5 5 each). (B) Hmgb12/2 (n 5 3) fetal liver cell chimeras compared with Hmgb11/1
chimeras (n5 5). (C) Hmgb12/2 chimeras compared with Hmgb12/2 chimeras receiving wild-type platelets, Hmgb12/2 platelets, or wild-type neutrophils. Dotted line indicates
mean in Hmgb11/1 bone marrow chimeras (n 5 3 each). (D) Tlr22/2 compared with control (n 5 4 each). (E) Tlr42/2 compared with control (n 5 4 each). (F) Rage2/2
compared with control (n 5 5 each). (G) Myd882/2 compared with control (n 5 4 each). The Student t test was used to compare results between 2 groups, 1-way
ANOVA followed by LSD–post hoc test for 3 groups.
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Figure 6. HMGB1 contributes to platelet accumulation in venous thrombosis. (A-G) Left, Immunofluorescence staining for CD41 (red) from cross-sections of the IVC.
Nuclei are counterstained with DAPI (blue); bar, 200 mm. Images representative of n 5 3 experiments. Right, Quantification of platelet-covered area. Results are mean 6
SEMT. (A) BoxA compared with control (n5 5 each). (B) Hmgb12/2 fetal liver cell chimeras (n5 3) compared with Hmgb11/1 chimeras (n5 5). (C) Left, Immunofluorescence
for CD41 in Hmgb12/2 chimeras compared with Hmgb12/2 chimeras receiving wild-type platelets, Hmgb12/2 platelets, or wild-type neutrophils (n 5 3 each). Right,
Quantification of platelet-covered area. Dotted line indicates mean in Hmgb11/1 bone marrow chimeras (n 5 3 each). (D) Tlr22/2 compared with control (n 5 3 each). (E)
Tlr42/2 compared with control (n 5 3 each). (F) Rage2/2 compared with control (n 5 5 each). (G) Myd882/2 compared with control (n 5 3 each). The Student t test was used
to compare results between 2 groups, 1-way ANOVA followed by LSD–post hoc test for 3 groups.
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Therefore, we determined the effect of HMGB1 inhibition by BoxA
on initial leukocyte accumulation by intravital microscopy and found
a significant reduction in BoxA-treated animals (supplemental
Figure 1D). Because neutrophils play an important role in DVT
formation,2,5,6 propagating the thrombotic process by releasing
prothrombotic NETs,6,44-47 we next focused on this leukocyte
subset. Inhibition of HMGB1 or lack of blood cell-derived HMGB1
had no significant effect on neutrophil accumulation, but signif-
icantly reduced NET formation (Figure 4A-D), suggesting that
HMGB1 acts prothrombotic at least in part by supporting NETosis.
Specificity of the staining was confirmed through isotype control
antibodies (supplemental Figure 2A). Consistent with the finding
thatHMGB1boostsNETformation throughRAGEinvitro,11NETosis
during DVT formation was virtually abolished in mice lacking RAGE,
whereas TLR2 and TLR4 appear to be dispensable for this process.
Also, Myd882/2 mice had a significantly decreased NET formation
(Figure 4E-H; supplemental Figure 2B-E). InfusionofWTplatelets, but
not of Hmgb12/2 platelets or WT neutrophils, into HMGB1-null
chimeras rescued the capacity of HMGB1-null neutrophils to form
NETs (Figure 4I; supplemental Figure 2F). Together, these data
implicate that platelet-derived HMGB1 increases the capacity of
neutrophils to form NETs in a process largely mediated by RAGE in
vivo.
Platelet derived HMGB1 supports monocytes accumulation
Although neutrophils are mainly important for propagation of DVT by
activating the intrinsic pathway of coagulation, monocytes initiate clot
formation by delivering TF that activates the extrinsic pathway.4,6
Inhibition of HMGB1 through BoxA resulted in a significantly
decreasedmonocyte recruitment as visualized by intravital microscopy
(supplemental Figure 3A). Deficiency of blood cell-derived HMGB1
resulted in significantly reduced monocyte accumulation within the
thrombus after 48 hours, which could be significantly increased byWT
platelets, but not by Hmgb12/2 platelets nor by wild-type neutrophils
(Figure 5A-C; supplemental Figure 3B). The DAMP receptors RAGE
and TLR2 mediated HMGB1-dependent monocyte accumulation
throughMyd88, whereas TLR4 had no significant effect (Figure 5D-G).
In summary, platelet-derived HMGB1 supports monocyte recruit-
ment to the developing venous thrombus through RAGE and TLR2
in a Myd88-dependent manner.
HMGB1 fosters platelet accumulation in venous thrombosis
Having shown that platelet HMGB1 drives sterile inflammation during
DVT, we next asked whether it also impacts on platelet recruitment
during venous thrombogenesis. Indeed, platelets do not only release
HMGB1, but are also activated by theDAMP in an autocrine/paracrine
manner.11,12,17,48,49 We found that BoxA treatment and even more so
lack of blood cell-derived HMGB1 decreased platelet recruitment
particularly at early stages of thrombus formation as assessed by
intravital microscopy and histology (Figure 6A-B; supplemental
Figure 3C-D). Reconstitution of Hmgb12/2 bone marrow chimeras
with wild-type platelets resulted in a trend toward increased platelet
accumulation,whereaswild-type neutrophils hadno effect (Figure 6C).
TLR2, TLR4, RAGE, and Myd88 deficiency each had no significant
effect on platelet accumulation after 48 hours (Figure 6D-G). Hence,
platelets are not only a source of HMGB1 in DVT, but their early
recruitment at the site of thrombus formation is also promoted by
HMGB1.
HMGB1 is rendered prothrombotic by oxidation
BecauseHMGB1not only boosts innate immune cell accumulation but
also modulates the activation of inflammatory cells depending on the
redox state, we next determined whether the prothrombotic effect
of HMGB1 is influenced by oxidation.15 Infusion of nonoxidizable
3S-HMGB1 into Hmgb12/2 chimeras could not significantly increase
thrombus formation and had no impact on the incidence of thrombosis.
However, disulfide HMGB1 significantly increased thrombus weight
as well as the incidence of thrombosis (Figure 7A). Analysis of these
thrombi indicated that disulfide HMGB1 significantly increased NET
formation and platelet accumulation compared with Hmgb12/2
chimeras, whereas monocyte recruitment could be only increased
nonsignificantly by both HMGB1 redox forms (Figure 7B-D;
supplemental Figure 3E-F).
Next, we determined in vitro whether the prothrombotic effect of
HMGB1 depends on the redox state. First, we determined the redox
form of HMGB1 in resting as well as activated platelets by mass
spectrometry: resting platelets contained reduced HMGB1, whereas
stimulation of platelet-rich plasma with thrombin resulted in the
formation of sulfonyl HMGB1 within 30 minutes (supplemental
Figure 4A-B). However, only disulfide HMGB1 significantly de-
creased clot formation time in extem tests indicating an effect on
platelets, whereas neither nonoxidizable 3S-HMGB1 nor sulfonyl
HMGB1 had an effect (Figure 7E). To analyze the impact of the
HMGB1 redox forms on platelets in more detail, we performedwhole-
blood aggregometry, where also only disulfide HMGB1 significantly
increased aggregation. In addition, we assessed whether the different
redox forms might sensitize platelets for a following stimulus and
preincubated whole blood first with HMGB1 and then stimulated it
withADP. In this setting, only the nonoxidizable form had a significant
effect. The aggregation induced by disulfide HMGB1 could not be
augmented further by subsequent stimulation with ADP (Figure 7F).
Because, disulfide HMGB1 significantly increased maximum clot
firmness in the Fibtem assay, excluding an effect on platelets, we
investigated the effect of HMGB1 on TF expression in monocytes,
which are the main source of TF in DVT (Figure 7E).6 Using real-time
reverse transcriptase polymerase chain reaction (RT-PCR), we could
show that only disulfide HMGB1 induced a significant upregulation of
TF as well as of the cytokines IL-6 and IL-1b (Figure 7G). Finally, we
characterized the impact of theHMGB1redox formsonNETformation
in vitro: disulfide HMGB1 was significantly more potent in inducing
NETosis than the reduced form, consistent with the in vivo results
(Figure 7H). These differences in the biological effect of different
Figure 7. The prothrombotic effects of HMGB1 depend on the redox state. (A) Thrombus weight in Hmgb12/2 chimeras (n 5 10) treated with buffer compared with
Hmgb12/2 chimeras (n 5 5 each) receiving 3S- or disulfide HMGB1. Lines indicate mean. (B) Quantification of NETs, (C), monocytes, (D), and platelet covered area from
immunofluorescence stainings of Hmgb12/2 chimeras receiving buffer, 3S-, or disulfide HMGB1 (n 5 3 each). (E) Extem (left) and Fibtem (right) 6 hours after IV injection of
3S- (n 5 3), disulfide HMGB1 (n 5 3), or sulfonyl (n 5 3) compared with control (n 5 5). (F) Fold increase in whole-blood aggregation after incubation with 3S-, disulfide, or
sulfonyl HMGB1 compared with control stimulated with buffer. This was followed by stimulation by ADP in the groups indicated (n 5 4-6). (G) Results from RT-PCR for TF
(left), IL-1b (middle), and IL-6 (right) of peripheral blood human monocytes incubated with different redox forms of HMGB1 and LPS for 3 hours shown as fold increase
compared with control stimulated with the respective buffer (n 5 3 each). (H) Left, Quantification of NET formation in vitro after stimulation of isolated human neutrophils with
buffer, 3S-, disulfide, or sulfonyl HMGB1 (n 5 3 each). Right, Representative images of immunofluorescence stainings for MPO (red) and Hoechst (blue); bar, 50 mm. Results
are mean 6 SEM. *P , .05. The Student t test was used to compare results between 2 groups, 1-way ANOVA followed by LSD–post hoc test for 3 groups.
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HMGB1 redox forms could be explained by their differential binding
to RAGE: SPR analysis showed a higher association rate of disul-
fide HMBG1 to RAGE compared with nonoxidizable HMBG1 and
sulfonyl HMBG1 at first glance. Because the sensorgrams did not
follow a typical 1:1 binding shape, we performed IM analysis to
discriminate between the different binding events. Interestingly, IM
analysis revealed 2 high-affinity binding events of nonoxidizable
HMBG1 (6 nM and 32 nM) and sulfonyl HMBG1 (0.2 nM and
120 nM) to RAGE. Whereas the overall affinities of the lower-affinity
binding events are similar for all 3 RAGE redox forms, the higher-
affinity binding event is indeed shaped not only by a higher association
rate for disulfide HMGB1, but also to a drastically higher dissociation
rate. For the sulfonyl HMGB1, the high-affinity binding is barely
detectable (12%peakweight) andmight explain its biological inactivity
(supplemental Figure 4 C-E). In conclusion, reducedHMGB1 released
from platelets is rendered prothrombotic by oxidation and disulfide
HMGB1 induces platelet aggregation, NET formation, and TF
production in monocytes.
Discussion
DVT is one of the most common cardiovascular disorders and has to
be considered a sterile inflammatory process that results in vessel
occlusion due to aberrant activation of immunothrombosis.3 Targeting
the inflammatory response that culminates in DVT formation could
therefore represent a promising strategy to treat or prevent DVT
formation without affecting physiological hemostasis. However,
although the cells triggering DVT formation have largely been
identified over the past years, the molecular cascades involved in
translating sterile inflammation into a thrombotic disorder remain
incompletely understood.2,4-6,45
Here, we identified HMGB1 as the key factor in the reciprocal
communication between platelets, neutrophils, and monocytes in-
ducing clot formation.6 We demonstrate that platelets deliver reduced
HMGB1 to the affected vein thereby inducing the recruitment and
activation of innate immune cells, particularly monocytes, in a process
involving RAGE, TLR2, and Myd88. Platelet-derived disulfide
HMGB1 also boosts monocyte TF and cytokine expression, triggers
the formation of prothrombotic NETs, and supports platelet accumu-
lation in an autocrine/paracrine fashion. Enhanced platelet accumula-
tion and NETosis in turn results in additional HMGB1 deposition
setting off a vicious circle propagating DVT formation (supplemental
Figure 5). Notably, unlike loss of blood cell-derived HMGB1,
deficiency of the known HMGB1 receptors TLR2, TLR4, or RAGE
was not sufficient to inhibit venous thrombus formation, but combined
deficiency of downstream signaling in Myd882/2 mice significantly
reduced thrombus formation. A contribution of the IL-1 receptor,
which also signals through Myd88, on thrombus formation could
be excluded. This indicates that HMGB1 acts on all receptors
synergistically and that these receptors have redundant functions in
DVT formation. Hence, our study identifies HGMB1 as a potential
new target for the treatment and prevention of DVT.
HMGB1 is a ubiquitous protein primarily found in the cell nucleus
and upon activation of cells HMGB1 can be actively secreted into the
extracellular space. In addition, cell necrosis results in uncontrolled
release of HMGB1 into the extracellular compartment.16,39 The
pathophysiological importance ofHMGB1as a trigger of inflammatory
responses has been documented in several disease settings, particularly
sepsis, where disseminated intravascular coagulation is augmented by
HMGB150 and even late inhibition of HMGB1 resulted in improved
survival in mice.10 In the setting of experimental microvascular
thrombosis induced by FeCl3, platelet-derived HMGB1 has recently
been demonstrated to contribute to the inflammatory response and
small vessel occlusion.17 Moreover, HMGB1 contributes to ischemia/
reperfusion injury andhas been shown to be a criticalmediator of sterile
muscle injury as seen in trauma.15,51-53
We could show here that during DVT, HMGB1 accumulates in
the absence of overt luminal or vascular cell necrosis and is delivered
by blood cells, mainly platelets, but at later stages also by NET-
ting neutrophils. In line with that, HMGB1 could be detected during
the resolution phase of DVT in murine venous thrombi.54 It has been
shown previously that platelets actively expose HMGB1 on their
surfaces after activation in vitro.12,48 In line with our observation in
mice, HMGB1 has recently been reported in human coronary artery
thrombi, where it also colocalized with platelets and NETs.11,34,35 This
is in contrast to scenarios dominated by tissue necrosis, whereHMGB1
mostly derived from dying cells within the tissue is important for
induction of the inflammatory response.55 Therefore, we could identify
activated platelets as themain source of HMGB1 in venous thrombosis
in vivo.
But how is HMGB1 involved in the prothrombotic cross-
communication between platelets, monocytes, and neutrophils
promoting venous thrombosis formation? For recruitment of innate
immune cells,mainly reduced all-thiolHMGB1 is important,which is
present in resting platelets and exposed after activation.35,56 Once
recruited to the vesselwall,myeloid leukocytes and activatedplatelets
in turn release reactive oxygen species, resulting in the formation
of disulfide HMGB1.15,35 It has been shown recently that in the
extracellular space HMGB1 is oxidized quickly: the half-life for all-
thiol HMGB1within the serum is 17minutes before it is oxidized into
disulfideHMGB1 invitro.57 In addition, in amodel of ischemic stroke
mainly all-thiol HMGB1 is found after 2 hours in serum samples,
whereas bothall-thiol anddisulfideHMGB1are foundafter 24hours.32
Therefore, reduced HMGB1 released from platelets is probably
oxidized quicklywithin the blood stream.DisulfideHMGB1 activates
immune cells and, as we show here, has profound prothrombotic
effects by promoting formation of NETs, platelet aggregation, and
TF expression of monocytes. Terminal oxidation to the inert sulfonyl
form of HMGB1 prevents an overshooting immune response. This
could be explained by different binding characteristics of the HMGB1
redox forms to RAGE. SPR and IM analysis suggest 2 binding sites
for HMBG1 on RAGE. In line with this, a second binding epitope
of HMGB1 to RAGE has been proposed recently.58 So far, only
1 binding site for HMGB1 on RAGE has been identified, but this was
never analyzedwith different HMGB1 redox forms.59-61Whereas 1 of
the 2 potential binding sites can be bound similarly by the different
HMBG1 redox variants, the other site probably discriminates between
the different redox states.We report here that RAGE, but not TLR2/4,
is involved inNETosis induced by platelet-derivedHMGB1 in venous
thrombosis. NETs in turn, provide a prothrombotic scaffold and
expose even more disulfide HMGB1 on their extracellular DNA
strands.62 Moreover, NETs have been shown to contribute to venous
as well as arterial thrombosis through other mechanisms,6,44,46,47
including their ability to bind and/or activate platelets, TF, and FXII
altogether leading to acceleration of thrombus formation.36,45,63
In addition to neutrophils, monocytes are essential for venous
thrombosis because they are themainsourceof blood-derivedTF in this
model.4,6 It has been demonstrated that HMGB1 induces monocyte
migration in vitro mediated by forming a complex with CXCL12 and
activating the CXCR4 receptor, while RAGE also contributes.64
Interestingly, heparin inhibits the binding of HMGB1 to macrophages,
thereby preventing their activation, a mechanism that might contribute
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to heparin’s antithrombotic activity.65 Here, we show in vivo that
platelet-derived HMGB1 is essential for the recruitment and
accumulation of monocytes in the setting of venous thrombosis
through RAGE and TLR2. Moreover, we could show that disulfide
HMGB1 induces the expression of TF, IL-6, and IL-1b in
monocytes. This initiates the extrinsic pathway of coagulation
and augments the activation status of innate immune cell.
Treatment of mice with the competitive HMGB1 antagonist BoxA
significantly decreased thrombus weight, but had no effect on the
incidence of thrombosis, implicating that BoxA impairs propaga-
tion of thrombosis rather than its initiation and is less potent than
deficiency of blood-derived HMGB1. Consistent with this, initial
monocyte recruitment was impaired, but accumulation of mono-
cytes was not significantly reduced in BoxA-treated mice, whereas
NET formation was abolished, which is mainly implicated in
propagation of venous thrombosis. Because HMGB1 induces the
expression of several chemokines and cytokines in addition to its
promigratory effects, long-term inhibition of HMGB1 could
potentially impair immune responses.15,16,37,55,64,66,67 However,
inhibition of HMGB1 over several days to weeks in the setting of
arthritis and atherosclerosis in mice had no reported negative effect
and mice were not prone to infection.68,69 In addition, inhibition of
HMGB1 in sepsis reduced lethality indicating that it could be a
target for regulation of overshooting immune responses.10,18
However, the long-term effects of HMGB1 inhibition in humans
might be different to mice.
During DVT, HMGB1 does not only coordinate sterile inflamma-
tion, but also directly acts on platelets in an autocrine/paracrine manner
supporting platelet recruitment in a positive feedback loop. This in turn
facilitates further leukocyte recruitment, monocyte activation, and
boosts NET formation.6 But how exactly does HMGB1 activate
platelets? In vitro, it has been shown that HMGB1 can bind to activated
platelets via RAGEandTLR4, leading to platelet activation in the latter
setting.34,49 For microvascular thrombosis, signaling of HMGB1
through TLR4 and Myd88 has been demonstrated to be involved in
platelet activation and granule secretion in vivo.17 However, this is
not exclusive because other DAMPs, including histones, can acti-
vate platelets through similar pattern recognition receptor–dependent
pathways.36 In the setting of venous thrombosis, we could not identify a
single receptor exclusively mediating all effects of HMGB1 on
platelets.This canbeexplainedby the absenceof anoxidizingagent like
FeCl3 in our model of macrovascular thrombosis in contrast to the
previous study addressingmicrovascular thrombosis.17Consistentwith
this,we showhere that the prothrombotic effects ofHMGB1depend on
the redox state of the DAMP protein: all-thiol HMGB1 sensitizes
platelets toward additional agonists, such as ADP, but has little direct
effects on platelet aggregation. In contrast, disulfide HMGB1 causes
aggregation of whole blood even in the absence of additional platelet
agonists.
In conclusion, using an in vivo model of macrovascular venous
thrombosis, we demonstrate that platelets contain all-thiol HMGB1,
and are the major source of HMGB1 in DVT. HMGB1 is exposed on
the platelet surface in its reduced form,but following release it is rapidly
oxidized to the disulfide and sulfonyl forms. The disulfide form of
HMGB1appears to bemost relevant forDVT, and in factwe found that
3S-HMGB1, which cannot be oxidized, and the sulfonyl form have
a limited impact on DVT. The different forms of redox HMGB1 act
via multiple receptors: CXCR4, activated by a complex between
reduced HMGB1 and CXCL12; TLR4, activated by disulfide
HMGB1; TLR2; and RAGE. Which redox forms interact with
TLR2 and RAGE was not previously clear; we provide evidence
here that all redox forms ofHMGB1 interact withRAGE, except the
disulfide form with higher affinity. In venous thrombosis, the order
of events starts with luminal accumulation of HMGB, which then
(1) recruits and activates monocytes to the developing thrombus,
promoting the oxidation to disulfide HMGB1, which in turn
provide TF thereby activating the extrinsic pathway of coagulation,
and proinflammatory mediators like IL-6 and IL-1b thereby
initiating a vicious circle of leukocyte recruitment and activation;
(2) induces NET formation through RAGE, which propagates DVT
development; (3) synergizes with NET-derived HMGB1 in venous
thrombus formation; and finally (4) fosters platelet activation in an
autocrine/paracrine manner mediated by oxidized HMGB1.
Therefore, different redox forms of HMGB1 orchestrate the inter-
play between platelets, neutrophils, and monocytes, which is nec-
essary for the development of venous thrombosis in vivo. This
DAMP might therefore be an attractive new target for anti-
inflammatory strategies in DVT prophylaxis.
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